Hainan Poly Pharm. Co., Ltd
SZSE:300630.SZ
20.3 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,304.483 | 1,806.345 | 1,508.829 | 1,188.603 | 950.095 | 623.904 | 324.827 | 248.009 | 202.823 | 164.562 | 132.457 | 111.181 |
| Cost of Revenue
| 351.512 | 616.961 | 428.854 | 300.033 | 174.764 | 101.352 | 55.306 | 57.67 | 51.648 | 44.337 | 37.825 | 35.038 |
| Gross Profit
| 952.971 | 1,189.384 | 1,079.976 | 888.57 | 775.331 | 522.553 | 269.521 | 190.34 | 151.175 | 120.225 | 94.632 | 76.143 |
| Gross Profit Ratio
| 0.731 | 0.658 | 0.716 | 0.748 | 0.816 | 0.838 | 0.83 | 0.767 | 0.745 | 0.731 | 0.714 | 0.685 |
| Reseach & Development Expenses
| 267.673 | 263.038 | 229.318 | 191.181 | 184.293 | 138.119 | 63.304 | 25.209 | 21.107 | 16.796 | 14.36 | 0 |
| General & Administrative Expenses
| 68.5 | 53.602 | 33.398 | 23.709 | 31.786 | 24.999 | 14.413 | 12.027 | 11.842 | 9.22 | 31.752 | 24.728 |
| Selling & Marketing Expenses
| 414.421 | 350.654 | 233.161 | 177.043 | 199.774 | 137.796 | 70.537 | 64.721 | 54.839 | 46.498 | 33.557 | 29.611 |
| SG&A
| 644.46 | 404.255 | 266.56 | 200.752 | 231.559 | 162.795 | 84.951 | 76.748 | 66.681 | 55.718 | 65.309 | 54.34 |
| Other Expenses
| -7.048 | -0.585 | -0.553 | -3.562 | 0.637 | 0.034 | 0.092 | 8.236 | 2.945 | 4.28 | 1.157 | 2.087 |
| Operating Expenses
| 905.085 | 707.188 | 548.669 | 404.125 | 424.417 | 316.123 | 155.17 | 119.068 | 102.795 | 84.568 | 67.288 | 55.657 |
| Operating Income
| 47.887 | 439.502 | 468.095 | 457.806 | 333.525 | 209.905 | 115.394 | 73.33 | 54.122 | 39.702 | 27.416 | 19.147 |
| Operating Income Ratio
| 0.037 | 0.243 | 0.31 | 0.385 | 0.351 | 0.336 | 0.355 | 0.296 | 0.267 | 0.241 | 0.207 | 0.172 |
| Total Other Income Expenses Net
| 26.934 | -0.585 | -0.553 | -3.562 | 0.637 | 0.034 | 0.092 | 7.721 | 2.839 | 3.871 | 1.157 | 2.086 |
| Income Before Tax
| 74.82 | 438.917 | 467.542 | 454.244 | 334.162 | 209.94 | 115.486 | 81.111 | 56.961 | 43.573 | 28.573 | 21.234 |
| Income Before Tax Ratio
| 0.057 | 0.243 | 0.31 | 0.382 | 0.352 | 0.336 | 0.356 | 0.327 | 0.281 | 0.265 | 0.216 | 0.191 |
| Income Tax Expense
| -11.103 | 18.301 | 50.939 | 46.793 | 33.015 | 28.512 | 17.081 | 11.333 | 6.26 | 6.908 | 3.782 | 5.908 |
| Net Income
| 85.923 | 420.616 | 416.603 | 407.451 | 301.147 | 181.427 | 98.404 | 69.779 | 50.702 | 36.665 | 24.79 | 15.326 |
| Net Income Ratio
| 0.066 | 0.233 | 0.276 | 0.343 | 0.317 | 0.291 | 0.303 | 0.281 | 0.25 | 0.223 | 0.187 | 0.138 |
| EPS
| 0.2 | 0.96 | 0.95 | 0.93 | 0.71 | 0.43 | 0.25 | 0.22 | 0.16 | 0.12 | 0.078 | 0.052 |
| EPS Diluted
| 0.19 | 0.9 | 0.95 | 0.93 | 0.71 | 0.43 | 0.25 | 0.22 | 0.16 | 0.12 | 0.078 | 0.052 |
| EBITDA
| 309.338 | 442.344 | 596.961 | 515.867 | 375.813 | 231.768 | 129.353 | 93.731 | 70.065 | 47.592 | 37.454 | 28.69 |
| EBITDA Ratio
| 0.237 | 0.332 | 0.409 | 0.447 | 0.407 | 0.379 | 0.402 | 0.379 | 0.333 | 0.288 | 0.287 | 0.263 |